Cosciens Biopharma Inc.TSX: CSCI

Aeterna Zentaris: Data and Safety Monitoring Board Recommends Continuation of ZoptEC Phase 3 Trial in Advanced Endometrial Cancer

· Issued by Cosciens Biopharma Inc.

Philip A. Theodore, Senior Vice President, ptheodore@aezsinc.comCopyright CNW Group 2015